Daily Journal masthead

Eli Lilly's 4Q profit jumped on sales of Humalog insulin and Cialis, topping Wall Street expectations


NEW YORK — Eli Lilly and Co. on Thursday reported a boost in fourth-quarter profit of on higher sales of its top-selling insulin Humalog and the erectile dysfunction drug Cialis.

The drugmaker's profit rose 12 percent to $478.4 million, or 45 cents per share. Earnings, adjusted for research and development costs and asset impairment costs, were 78 cents per share.

The results exceeded Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 77 cents per share.

The Indianapolis-based company's revenue rose 5 percent to $5.38 billion in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $5.28 billion.

Sales of Humalog rose 10 percent to $798.7 million, making it the company's top-selling drug. That boost helped offset a 13 percent decline in sales of the cancer drug Alimta, which is facing generic competition. Meanwhile, Cialis sales rose 3 percent to $638.4 million.

For the year, the company reported profit of $2.41 billion, or $2.26 per share. Revenue was reported as $19.96 billion.

Lilly expects full-year earnings in the range of $3.45 to $3.55 per share, with revenue in the range of $20.2 billion to $20.7 billion.

Lilly shares have declined 3 percent since the beginning of the year, while the Standard & Poor's 500 index has decreased almost 8 percent. The stock has increased 14 percent in the last 12 months.


Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LLY at http://www.zacks.com/ap/LLY


Keywords: Eli Lilly, Earnings Report

Think your friends should see this? Share it with them!

Story copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Feedback, Corrections and Other Requests: AP welcomes feedback and comments from readers. Send an email to info@ap.org and it will be forwarded to the appropriate editor or reporter.

We also have more stories about:
(click the phrases to see a list)


Follow Daily Journal:

All content copyright ©2016 Daily Journal, a publication of AIM Media Indiana unless otherwise noted.
All rights reserved. Privacy policy.